This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Shingles
  • /
  • Updated Recommendations on the Use of Herpes Zoste...
Guideline

Updated Recommendations on the Use of Herpes Zoster VaccinesUpdated Recommendations on the Use of Herpes Zoster Vaccines

Read time: 1 mins
Last updated:29th Aug 2018
Status: Live
An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) - Updated Recommendations on the Use of Herpes Zoster Vaccines


The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.

The need for this updated National Advisory Committee on Immunization (NACI)Advisory Committee Statement on the Use of Herpes Zoster (HZ)Vaccines was triggered by evidence on anewly authorized Recombinantsubunit Zoster Vaccine (RZV)vaccine, Shingrix®, indicated for the prevention of HZ in individuals 50 years of age and older.The primary objective of this statement is to review currentevidence and develop guidance on the use of Shingrix®, as well as to provide guidance on whetherthe previously authorized Live Zoster Vaccine(LZV), Zostavax®II,and/or the recently authorized RZVshould be offered to Canadians ≥50 years of age and older:
- at a population-level, in publicly funded immunization programs
- at an individual-level, to individuals wishing to prevent HZ,or by clinicians wishing to advise individual patientsabout preventing HZ, with vaccines that may not currently be included in public health immunization programs.

Read full Guideline